Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study

PurposeTo retrospectively evaluate and compare treatment effectiveness and safety between transarterial chemoembolization (TACE) combined with molecularly targeted agents plus immune checkpoint inhibitors (TACE+T+I) and TACE combined with molecularly targeted agents (TACE+T) for unresectable hepatoc...

Full description

Bibliographic Details
Main Authors:	Nan Jiang, Binyan Zhong, Jintao Huang, Wanci Li, Shuai Zhang, Xiaoli Zhu, Caifang Ni, Jian Shen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Immunology
Subjects:	transarterial chemoembolization targeted therapy immune therapy unresectable hepatocellular carcinoma combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1205636/full

Similar Items

Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
by: Deng L, et al.
Published: (2024-01-01)

Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: a retrospective controlled study
by: Song Chen, et al.
Published: (2023-11-01)

Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials
by: Han Dong, et al.
Published: (2023-06-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
by: Jin M, et al.
Published: (2024-11-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
by: Yue Han, et al.
Published: (2021-10-01)

Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Weiwei Li, et al.
Published: (2022-08-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
by: Jiang J, et al.
Published: (2024-08-01)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
by: Xue-Gang Yang, et al.
Published: (2022-07-01)

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
by: Wu SJ, et al.
Published: (2023-06-01)

Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
by: Yue Chen, et al.
Published: (2024-08-01)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-02-01)

Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
by: Yu B, et al.
Published: (2023-10-01)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-06-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01)

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
by: Haidong Ai, et al.
Published: (2024-05-01)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
by: Jinpeng Li, et al.
Published: (2023-07-01)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
by: Shao W, et al.
Published: (2019-11-01)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
by: Qunfang Zhou, et al.
Published: (2020-11-01)

A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
by: Zhi-Mei Huang, et al.
Published: (2024-01-01)

Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory
by: Yan-Jun Xiang, et al.
Published: (2022-03-01)

Therapeutic efficacy and safety of Compound Kushen Injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An update systematic review and meta-analysis
by: Xiao eMa, et al.
Published: (2016-03-01)

Factors Predicting Survival after Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma
by: Farina M. Hanif, et al.
Published: (2014-10-01)

Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
by: Changlong Hou, et al.
Published: (2024-03-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
by: Hongyu Pan, et al.
Published: (2025-03-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
by: Shen X, et al.
Published: (2024-10-01)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020-01-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7
by: Jiang JQ, et al.
Published: (2023-09-01)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang JX, et al.
Published: (2022-03-01)

Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma
by: Al Fuhaid Turki, et al.
Published: (2007-01-01)

Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study
by: Jason Chiang, et al.
Published: (2023-11-01)

Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
by: Hao Li, et al.
Published: (2023-11-01)

Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma
by: You-Bin Wang, et al.
Published: (2023-09-01)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
by: Lei Zhang, et al.
Published: (2020-09-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
by: Jiashuo Chao, et al.
Published: (2021-03-01)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Lin Li, et al.
Published: (2018-09-01)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
by: Jun Deng, et al.
Published: (2022-03-01)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
by: Shuguang Ju, et al.
Published: (2022-03-01)